2024-04747. Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA LLC  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Sterling Pharma USA LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 6, 2024. Such persons may also file a written request for a hearing on the application on or before May 6, 2024.

    ADDRESSES:

    The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission Start Printed Page 16031 of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on January 9, 2024, Sterling Pharma USA LLC., 10001 Sheldon Drive, Suite 101, Cary, North Carolina 27513, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

    Controlled substanceDrug codeSchedule
    Tetrahydrocannabinols7370I
    5-Methoxy-N-N-dimethyltryptamine7431I
    Dimethyltryptamine7435I
    Psilocybin7437I
    Psilocyn7438I

    The company plans to manufacture the above-listed controlled substance(s) to support clinical trials. No other activities for these drug codes are authorized for this registration.

    Start Signature

    Marsha Ikner,

    Acting Deputy Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2024–04747 Filed 3–5–24; 8:45 am]

    BILLING CODE P

Document Information

Published:
03/06/2024
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2024-04747
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 6, 2024. Such persons may also file a written request for a hearing on the application on or before May 6, 2024.
Pages:
16030-16031 (2 pages)
Docket Numbers:
Docket No. DEA-1328
PDF File:
2024-04747.pdf